| Lightcalls.com |
|
|
![]() |
Asthma affects approximately three ...Asthma affects approximately three percent of all Americans. Marked by way of coughing, wheezing, shortness of breath, and tightness in the chest, air pollution is known to exacerbate its symptoms. Other asthma-episode provoking factors include: frosty air, stress, food allergens/chemicals (such as BHA, BHT and sulfites used to maintain salads and other restaurant fare, as well as forage colorants-such as FD & C golden #5), respiratory infections, pollens, and airborne chemical pollutants used by all to large, more polluted, cities. Asthma, itself, is caused by the agency of spasms in the muscles around the bronchi (small airways in the lungs) which restrict the passage of air. When the air passages are affected in of the like kind a way that air cannot pass unhindered to and from the tiny air sacs (bronchioli) in the lung bronchial asthma results The biochemical causes of the actual spasms are related, in part, to the production of histamine from our body's own immune arrangement during an allergic response, specifically released on mast cells and basophils. In addition, heightened on a levels of inflammatory chemicals and other enclosed spaces typically associated with allergic immune response--prostaglandins and eosinophils -- are seen before and during episodes of asthma and bronchial asthma. Allergic rhinitis is marked by dint of swelling of the mucous membrane inside the nasal passage associated with sneezing and a suitable deal of nose-blowing. Thankfully, there are Ayurvedic botanicals which have been known for untold centuries for their beneficial anti-asthma/anti-allergy effects One Ayurvedic plant which helps: Tylophora indica A prime example of an Ayurvedic botanical traditionally used for the aforementioned conditions is Tylophora indica (also called Tylophora asthmatica). Found growing wild in India's plains, it also improves in the forests and hilly areas of southern and eastern India, North and East Bengal (a state in India), in the Assam Hills of northeast India, in Bangladesh's city, Chittagong, in India's Deccan Peninsula (south of the Narbada River), and in Sri Lanka (Ceylon) in addition to other areas. Called Moolini in Sanskrit and Antamul in Hindi, T indica is a delicate creeping plant, dark cauldron in color. Aside from alkaloids, this plant has been institute to contain: cetyl alcohol, resin, chlorophyll, tannins, calcium salts, and potassium chloride. Further examining asthma and allergic rhinitis Early work: 1969-1979 Early (modern) research into this botanical was carried revealed by such researchers as Sri GB Kotak, whose work was continued by dint of D.N. Shivpuri, M.D., et al., in brace landmark studies that appeared in 1968 and 1969 The 1969 contemplation entitled "A Crossover Double-Blind consideration on Tylophora indica in the Treatment of Asthma and Allergic Rhinitis," contemplateed at treatment with T. indica onward 110 patients with bronchial asthma, patients who received either the Ayurvedic plant or a dummy pill, or placebo (in this case, spinach). At the close of one week, 62 percent of the T indica arrange "had complete to moderate relief in symptoms, as compared with 28 percent of the placebo group" the contemplation states. This is important because, although initially the dummy (placebo) general intent was high (45.16 percent), this power decreased dramatically, to the point where, at 12 weeks, the percentage of population with "complete to moderate relief" was 16 percent while the placebo purport was nonexistent, a success rate 16 times as effective. In 1972 Shivpuri's team one time again took on T indica, in this case in an on a level larger crossover, double-blind study. One hundr ninety-five patients suffering from bronchial asthma onward a daily basis were placed into sum of two units groups, with 103 volunteers assigned to receive T indica. At the period of the first week, 563 percent of patients in the "Tylophora Group" experienced unimpaired to moderate improvement of symptoms, as compared to 316 percent in the placebo group At the cessation of 12 weeks, approximately 15 percent of the appendixed patients had achieved complete to moderate relief of symptoms compared to no patients with total relief in the placebo group In their discussion, the authors state: "We do not claim that the alcoholic extract of Tylophora indica therapys asthma, but the results of our double-blind trial pretend to indicate that, even with a small dose of 40 mg of extract administered one time daily for six days... [this plant] present the appearances to possess an extraordinary peculiarity of relieving symptoms of asthma to varying measures in a significant number of patients.... We are not aware of any other [botanical] which possesse this remarkable property" In a provocative animal-model close attention from 1972, P.S. Haranath and s Shyamalakumari observed T. asthmatica's (the name used in this case) efficiencys on experimentally-induced allergic, hypersensitivity reaction (anaphylaxis). The authors conclud that "the not past nor future study shows that the aqueous (liquid) extract of TA (T asthmatica) can interrupt experimentally-induced anaphylaxis." In a 1978 comparison of T indica and a standard anti-asthma remedy (a combination of ephedrine hydrochloride, theophylline, and phenobarbitone) in patients with bronchial asthma, authors KV Thiruvengadam, et al., conclud that "there was a sustained rise in maximum breathing capacity (MBC) vital capacity (VC) and peak expiratory emanate rate (PEFR) with the leaf (plant extract) as compared with the placebo." |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |